BPA Call 36C24124A0014-36C24124N0337
- Exosome Diagnostics Inc., a Bio-Techne Corporation subsidiary based in Waltham, Massachusetts, received a delivery order award from Veterans Integrated Service Network (VISN) 7 on April 1, 2021, for its ExoDx Prostate (IntelliScore) diagnostic testing services. The delivery order, valued at $438,951.68 on a firm fixed-price basis, is issued under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II) and does not utilize a set-aside designation. Performance...
- Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, was awarded a $692,149.52 firm fixed-price delivery order by Veterans Integrated Service Network 6 (VISN 6) on May 13, 2022, for the provision of ExoDx Prostate (IntelliScore) testing services. The contract, which is a child award under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II), requires performance through September 30, 2026, at the Richmond, VA location. This non-invasive,...
- Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, received a Blanket Purchase Agreement (BPA) call valued at $103,709.76 from Veterans Integrated Service Network 1 (VISN 1), a component of the Department of Veterans Affairs. The award, issued on December 15, 2024, is for the provision of ExoDx Prostate IntelliScore testing services, a non-invasive, urine-based liquid biopsy diagnostic test that analyzes exosomal RNA biomarkers to assess the risk of clinically significant prostate...
- This is a Year 3 task order issued against a parent Blanket Purchase Agreement (BPA) held by Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation specializing in advanced liquid biopsy diagnostic technologies. The task order, valued at $270K and awarded December 15, 2025, by Veterans Integrated Service Network 1 (VISN 1) under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II), will deliver approximately 360 ExoDx Prostate IntelliScore tests...
- Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, was awarded a $384,026.72 firm fixed-price delivery order by Veterans Integrated Service Network 2 on October 1, 2024, for ExoDx Prostate Test IntelliScore biopsies at the Northport VA Medical Center in New York. The contract, which is a child award under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II), carries an ultimate completion date of September 30, 2029, and involves no set-aside...
- This is a $9,018.24 firm fixed price purchase order awarded to Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 4 (VISN 4). The contract is for TESTING services, with a period of performance through December 11, 2024. There is no set-aside designation indicated. Exosome Diagnostics is a provider of liquid biopsy tests and laboratory services, primarily focused on non-invasive cancer detection and...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 6 awarded Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, a $0.00 firm fixed price delivery order against the Medical Laboratory Testing and Analysis Services (FSS-621-II) GSA Schedule. The order is for EXO DX OPTION YR 1 services with a period of performance through September 30, 2022. No set-aside designation was used for this award. Exosome Diagnostics will provide...
- This is a $8,266.72 firm fixed price delivery order contract awarded to Exosome Diagnostics, Inc., a subsidiary of Bio-Techne Corporation, by the U.S. Department of Veterans Affairs (VA). The contract is for the provision of the ExoDx Prostate (IntelliScore) non-invasive, urine-based liquid biopsy test to support prostate cancer screening for veterans at the Northport VA Medical Center. This contract was awarded under the VA's Medical Laboratory Testing and Analysis Services Federal Supply...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 6 awarded a $1,503.04 delivery order against the Medical Laboratory Testing and Analysis Services (FSS-621-II) multiple award schedule to Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation. The firm fixed price order is for exosome diagnostic services to support the agency's medical testing programs. Performance will take place in Waltham, Massachusetts with a period of performance...
- Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division, was awarded a task order valued at $3,116 under a Blanket Purchase Agreement (BPA) call for Oncotype DX Testing Services by the Department of Veterans Affairs' Veterans Integrated Service Network 15 (VISN 15). The award, issued on March 16, 2026, with an ultimate completion date of March 15, 2027, is structured as a firm fixed-price contract with no set-aside designation. Performance will take place in Marion,...
- Medical Laboratory Testing and Analysis Services (FSS-621-II)Master GSA Schedule
- 36F79720D0097-36C24124A0014Blanket Purchase Agreement
- 36C24124A0014-36C24124N0337BPA Call
Exosome Diagnostics Inc., a Bio-Techne Corporation subsidiary based in Waltham, Massachusetts, received a $69,891.36 firm fixed-price task order from the Department of Veterans Affairs Veterans Integrated Service Network 1 (VISN 1) for ExoDx Prostate IntelliScore testing services. This contract, awarded January 15, 2024, with completion by December 14, 2024, represents a child task order issued against the company's parent Blanket Purchase Agreement valued at $1.35M. The ExoDx Prostate IntelliScore test is a non-invasive, urine-based liquid biopsy that analyzes exosomal RNA biomarkers to assess the risk of clinically significant prostate cancer in veterans. The award is classified as a sole-source procurement under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II) with no set-aside designation, reflecting Exosome Diagnostics' unique diagnostic capabilities in this specialized market. The VA VISN 1 has established a strategic relationship with Exosome Diagnostics to support prostate cancer screening initiatives across its healthcare network, with the parent BPA structured to provide approximately 1,800 tests over five years and an estimated 360 units annually. This task order exemplifies the VA's continued reliance on innovative liquid biopsy technologies to enhance cancer detection capabilities for eligible veterans. Exosome Diagnostics has demonstrated significant contract success across multiple Veterans Integrated Service Networks, with delivery orders ranging from approximately $8,000 to $692,000, underscoring the company's established position as the VA's primary provider of advanced exosomal RNA biomarker testing services for oncology-related healthcare initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Supplemental Agreement for work within scope | ($656) | 5/5/25 | |
| P00001 | Supplemental Agreement for work within scope | ($200k) | 10/8/24 | |
| Not listed | Not listed | $270.5k | 1/12/24 |